Acquisition Pending
GSK acquisition of Nuvalent
US$11bn equity value
Announced 9 Jun 2026 · US$124.00 cash per share · 40% premium
Advisers
Nuvalent
Target
- Financial adviser
- Legal adviser
- Fairness opinion
GSK
Acquirer
- Financial adviser
- Legal adviser
- The Information Agent
Investor
- Legal adviser
- Target
- Nuvalent
- Acquirer
- GSK
- Target based in
- United States
- Buyer based in
- United Kingdom
- Sector
- Biotech
- Tags
- Biotech, Oncology, Drug Development
In the league tables
- M&A financial advisers, 2026 to date Centerview Partners #5 · Citi #7 · Jefferies #14 · Leerink Partners #27
- M&A legal advisers, 2026 to date Davis Polk #6 · Sidley Austin #13 · Sullivan & Cromwell #14 · Ropes & Gray #25 · Slaughter and May #59
- Fairness opinion providers, 2026 to date Centerview Partners #4
Similar deals
- Merck & Co. acquisition of Terns Pharmaceuticals Mar 2026 · US$6.7bn · Biotech
- Gilead Sciences acquisition of Tubulis Apr 2026 · US$3.1bn · Biotech
- Eli Lilly and Company acquisition of Ajax Therapeutics Apr 2026 · US$2.3bn · Biotech
- Novartis acquisition of Pikavation Mar 2026 · US$2bn · Biotech
- Amgen acquisition of Dark Blue Therapeutics Jan 2026 · US$840m · Biotech
Sources
- 9 Jun 2026 Tender offer communication (SC TO-C), Nuvalent, Inc. sec.gov
- 9 Jun 2026 Target tender offer communication (SC14D9C), Nuvalent, Inc. sec.gov
- 9 Jun 2026 GSK $10.6 billion acquisition of Nuvalent davispolk.com
- 10 Jun 2026 S&C Advises Investor Deerfield on GSK’s $10.6 Billion Acquisition of Nuvalent sullcrom.com
- 24 Jun 2026 Tender offer statement (SC TO-T), Nuvalent, Inc. sec.gov
- 24 Jun 2026 Target response to tender offer (SC 14D9), Nuvalent, Inc. sec.gov





